MAIA Biotechnology Net Worth
MAIA Biotechnology Net Worth Breakdown | MAIA |
MAIA Biotechnology Net Worth Analysis
MAIA Biotechnology's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including MAIA Biotechnology's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of MAIA Biotechnology's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform MAIA Biotechnology's net worth analysis. One common approach is to calculate MAIA Biotechnology's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares MAIA Biotechnology's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing MAIA Biotechnology's net worth. This approach calculates the present value of MAIA Biotechnology's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of MAIA Biotechnology's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate MAIA Biotechnology's net worth. This involves comparing MAIA Biotechnology's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into MAIA Biotechnology's net worth relative to its peers.
Enterprise Value |
|
To determine if MAIA Biotechnology is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding MAIA Biotechnology's net worth research are outlined below:
| MAIA Biotechnology generated a negative expected return over the last 90 days | |
| MAIA Biotechnology has high historical volatility and very poor performance | |
| MAIA Biotechnology may become a speculative penny stock | |
| MAIA Biotechnology has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (19.77 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| MAIA Biotechnology currently holds about 8.15 M in cash with (13.07 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.75. | |
| Roughly 17.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from finance.yahoo.com: MAIA Biotechnology to Present at Biotech Showcase 2025 |
MAIA Biotechnology uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in MAIA Biotechnology. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to MAIA Biotechnology's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 22nd of March 2024 Upcoming Quarterly Report | View | |
| 13th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 22nd of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Follow MAIA Biotechnology's market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 49.18 M.Market Cap |
|
Project MAIA Biotechnology's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (2.35) | (2.47) | |
| Return On Capital Employed | (8.83) | (8.38) | |
| Return On Assets | (2.35) | (2.47) | |
| Return On Equity | (47.62) | (45.24) |
When accessing MAIA Biotechnology's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures MAIA Biotechnology's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of MAIA Biotechnology's profitability and make more informed investment decisions.
Please note, the presentation of MAIA Biotechnology's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, MAIA Biotechnology's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of MAIA Biotechnology's management manipulating its earnings.
Evaluate MAIA Biotechnology's management efficiency
MAIA Biotechnology has return on total asset (ROA) of (1.0711) % which means that it has lost $1.0711 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (5.5956) %, meaning that it created substantial loss on money invested by shareholders. MAIA Biotechnology's management efficiency ratios could be used to measure how well MAIA Biotechnology manages its routine affairs as well as how well it operates its assets and liabilities. As of February 2, 2025, Return On Tangible Assets is expected to decline to -2.47. The current year's Return On Capital Employed is expected to grow to -8.38. At present, MAIA Biotechnology's Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Debt To Assets is expected to grow to 0.59, whereas Total Assets are forecasted to decline to about 7.3 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.03 | 0.03 | |
| Tangible Book Value Per Share | 0.03 | 0.03 | |
| Enterprise Value Over EBITDA | (0.48) | (0.45) | |
| Price Book Value Ratio | 29.24 | 30.71 | |
| Enterprise Value Multiple | (0.48) | (0.45) | |
| Price Fair Value | 29.24 | 30.71 | |
| Enterprise Value | 9.6 M | 9.1 M |
The operational strategies employed by MAIA Biotechnology management play a crucial role in its market positioning. Assessing these strategies alongside financial data helps us evaluate the stock's investment potential.
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific MAIA Biotechnology insiders, such as employees or executives, is commonly permitted as long as it does not rely on MAIA Biotechnology's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases MAIA Biotechnology insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
MAIA Biotechnology time-series forecasting models is one of many MAIA Biotechnology's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary MAIA Biotechnology's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
MAIA Biotechnology Earnings per Share Projection vs Actual
MAIA Biotechnology Corporate Management
| MD MBA | President, CoFounder | Profile | |
| Joseph McGuire | Chief Officer | Profile | |
| Sergei Gryaznov | Chief Officer | Profile | |
| Jeffrey Himmelreich | Head Finance | Profile | |
| Mihail MD | Chief Devel | Profile | |
| Linda Moreira | Company Secretary | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in MAIA Biotechnology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. For information on how to trade MAIA Stock refer to our How to Trade MAIA Stock guide.You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of MAIA Biotechnology. If investors know MAIA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about MAIA Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of MAIA Biotechnology is measured differently than its book value, which is the value of MAIA that is recorded on the company's balance sheet. Investors also form their own opinion of MAIA Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is MAIA Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because MAIA Biotechnology's market value can be influenced by many factors that don't directly affect MAIA Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between MAIA Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if MAIA Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, MAIA Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.